Siemens AG And University of California, Los Angeles (UCLA) Researchers Get FDA “Green Light” For Clinical Study Of Alzheimer’s-Specific Imaging Agent

HOFFMAN ESTATES, Ill. & LOS ANGELES--(BUSINESS WIRE)--Siemens Medical Solutions announced today that it will begin clinical trials under an investigational new drug (IND) application submitted to the Food and Drug Administration (FDA) for a breakthrough imaging biomarker that could potentially identify Alzheimer’s disease prior to the onset of noticeable symptoms.